SCHEMBL14728254

SCHEMBL14728254

CC1(C)CCc2c(c(Cl)n3c(nc4ccccc43)c2C#N)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
NPSR1 Q6W5P4 6/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
LMNA P02545 4/20 0.52
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
MDM2 Q00987 1/20 0.52
HSP90AA1 P07900 1/20 0.51
KDM4E B2RXH2 10/20 0.50
ALDH1A1 P00352 5/20 0.50
GLA P06280 3/20 0.50
GAA P10253 2/20 0.50
POLB P06746 1/20 0.50
XBP1 P17861 1/20 0.50
KMT2A Q03164 5/20 0.49
HTT P42858 3/20 0.49
HPGD P15428 2/20 0.49
MEN1 O00255 4/20 0.48
RXFP1 Q9HBX9 2/20 0.48
CYP1A2 P05177 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728253 0.91 MAPT (0.56) MAPTNPSR1SMN1; SMN2LMNARAB9A
SCHEMBL14728528 0.83 MAPK1 (0.59) MAPTNPSR1SMN1; SMN2LMNAKDM4E
SCHEMBL14716159 0.82 KDM4E (0.65) MAPTNPSR1SMN1; SMN2LMNARAB9A
SCHEMBL30630102 0.82 KDM4E (0.62) MAPTNPSR1SMN1; SMN2LMNARAB9A
SCHEMBL14728525 0.81 MAPK1 (0.54) MAPTNPSR1SMN1; SMN2LMNAKDM4E
SCHEMBL14728527 0.81 MAPK1 (0.54) MAPTNPSR1LMNAKDM4EALDH1A1
SCHEMBL14728533 0.79 MAPK1 (0.52) MAPTNPSR1LMNAKDM4EALDH1A1
SCHEMBL14728610 0.78 MAPK1 (0.47) MAPTNPSR1SMN1; SMN2LMNAKDM4E
SCHEMBL14728574 0.78 KDM4E (0.57) MAPTNPSR1LMNAKDM4EALDH1A1
SCHEMBL14728264 0.78 PDE4B (0.53) MAPTNPSR1SMN1; SMN2LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE PDE4B, PDE4A, PDE4C MAPT 411/4885NPSR1 2690/4885SMN1; SMN2 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.